Effect of Long Biliopancreatic Limb RYGB on Weight Loss and Comorbidities

'Effect of Long biLiopancrEatic Limb lenGth in lAparoscopic Roux-eN-Y Gastric Bypass on Weight Loss and Comorbidities in Patients With Morbid obEsity: a Prospective Randomized Control Trial'

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01686997

Acronym

Elegance

Enrollment

280

Registered

2012-09-18

Start date

2012-07-31

Completion date

2016-04-30

Last updated

2016-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity

Keywords

Bariatric surgery, Roux-en-Y Gastric Bypass

Brief summary

Morbid obesity is an increasing medical problem in the western countries. It's related to comorbidities as diabetes mellitus, hypertension, OSAS, arthrosis and hypercholesterolemia. The Roux-en-Y Gastric Bypass (RYGB) is an effective surgical therapy for morbidly obese patients. A part of these patients will have disappointing results, and have weight regain on the long term. Some studies show more weight reduction by increasing the biliopancreatic limb in patients with morbid obesity. The objective of this study is to investigate the effect of variations in the length of biliopancreatic limb on weight reduction in morbidly obese patients undergoing RYGB-surgery. We hypothesize that longer biliopancreatic limb results in more weight reduction. The study design is a prospective, randomized control trial. The patients will be randomized in 2 groups: a standard RYGB (short biliopancreatic limb) and long biliopancreatic limb RYGB.

Interventions

PROCEDURERoux-en-Y Gastric Bypass

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

Patient eligible for bariatric surgery according Fried guidelines Primary Gastric bypass * BMI 35 - 40 with a comorbidity * or BMI \> 40 Redo- operation * medical history: gastric sleeve/ mason / gastric band * all BMI levels

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Weight reduction	2 years	excess weight loss (%EWL)

Secondary

Measure	Time frame	Description
Decrease in comorbidities	2 years	diabetes mellitus, hypertension, hypercholesterolemia, arthrosis
Quality of life	2 years	SF-36 and BAROS
Complications and re-operations	2 years	bleeding, wound infections, intra-abdominal abcess, anastomosis leakage, vitamine deficiencies

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026